1.Occupational Lymphohematopoietic Cancer in Korea.
Eun A KIM ; Won Jin LEE ; Mia SON ; Seong Kyu KANG
Journal of Korean Medical Science 2010;25(Suppl):S99-S104
The purpose of this study was to review the existing studies on lymphohematopoietic (LHP) cancer in Korea, estimate the prevalence of workers exposed to carcinogens, and determine the population attributable fraction (PAF) of leukemia. Two case series and 4 case reports were reviewed. Using official statistics, the prevalence of benzene exposure and ionizing radiation exposure was estimated. Based on the prevalence of exposure and the relative risk, The PAF of leukemia was calculated. Between 1996 and 2005, 51 cases of LHP cancer were reported from the compensation system. Greater than 50% of occupational LHP cancer was leukemia, and the most important cause was benzene. In a cohort study, the standardized incidence ratio was 2.71 (95% CI, 0.56-7.91). The prevalence of exposure was 2.5% and 2.2% in 1995 and 2000, respectively. Using the 1995 prevalence, 3.6-4.8% and 0.1% of cases with leukemia were attributable to benzene and ionizing radiation exposure, respectively, which resulted in 39.7-51.4 cases per year. Benzene is the most important cause of occupational leukemia in Korea. Considering the estimated PAF in this study, the annual number of occupational LHP cancer (51 cases during 10-yr period), might be underreported within the compensation system.
Adult
;
Benzene/toxicity
;
Cohort Studies
;
Female
;
Humans
;
Incidence
;
Leukemia/*chemically induced/*epidemiology
;
Leukemia, Radiation-Induced/*epidemiology
;
Male
;
Middle Aged
;
Occupational Diseases/*epidemiology/etiology
;
Occupational Exposure/*adverse effects
;
Prevalence
;
Radiation, Ionizing
;
Republic of Korea/epidemiology
;
Workers' Compensation
2.Venous thromboembolism in children with acute lymphoblastic leukemia in China: a report from the Chinese Children's Cancer Group-ALL-2015.
Mengmeng YIN ; Hongsheng WANG ; Xianmin GUAN ; Ju GAO ; Minghua YANG ; Ningling WANG ; Tianfeng LIU ; Jingyan TANG ; Alex W K LEUNG ; Fen ZHOU ; Xuedong WU ; Jie HUANG ; Hong LI ; Shaoyan HU ; Xin TIAN ; Hua JIANG ; Jiaoyang CAI ; Xiaowen ZHAI ; Shuhong SHEN ; Qun HU
Frontiers of Medicine 2023;17(3):518-526
Venous thromboembolism (VTE) is a complication in children with acute lymphoblastic leukemia (ALL). The Chinese Children's Cancer Group-ALL-2015 protocol was carried out in China, and epidemiology, clinical characteristics, and risk factors associated with VTE were analyzed. We collected data on VTE in a multi-institutional clinical study of 7640 patients with ALL diagnosed in 20 hospitals from January 2015 to December 2019. First, VTE occurred in 159 (2.08%) patients, including 90 (56.6%) during induction therapy and 108 (67.92%) in the upper extremities. T-ALL had a 1.74-fold increased risk of VTE (95% CI 1.08-2.8, P = 0.022). Septicemia, as an adverse event of ALL treatment, can significantly promote the occurrence of VTE (P < 0.001). Catheter-related thrombosis (CRT) accounted for 75.47% (n = 120); and, symptomatic VTE, 58.49% (n = 93), which was more common in patients aged 12-18 years (P = 0.023), non-CRT patients (P < 0.001), or patients with cerebral thrombosis (P < 0.001). Of the patients with VTE treated with anticoagulation therapy (n = 147), 4.08% (n = 6) had bleeding. The VTE recurrence rate was 5.03% (n = 8). Patients with VTE treated by non-ultrasound-guided venous cannulation (P = 0.02), with residual thrombus (P = 0.006), or with short anticoagulation period (P = 0.026) had high recurrence rates. Thus, preventing repeated venous puncture and appropriately prolonged anticoagulation time can reduce the risk of VTE recurrence.
Humans
;
Child
;
Venous Thromboembolism/etiology*
;
East Asian People
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/epidemiology*
;
Risk Factors
;
Thrombosis/chemically induced*
;
China/epidemiology*
;
Anticoagulants/adverse effects*
;
Recurrence
3.Selective Bowel Decontamination for the Prevention of Infection in Acute Myelogenous Leukemia: A Prospective Randomized Trial.
Dong Gun LEE ; Su Mi CHOI ; Jung Hyun CHOI ; Jin Hong YOO ; Yoon Hee PARK ; Yoo Jin KIM ; Seok LEE ; Chang Ki MIN ; Hee Je KIM ; Dong Wook KIM ; Jong Wook LEE ; Woo Sung MIN ; Wan Shik SHIN ; Chun Choo KIM
The Korean Journal of Internal Medicine 2002;17(1):38-44
BACKGROUND: Infection is still a frequent cause of morbidity and mortality in acute myelogenous leukemia (AML) patients receiving chemotherapy. Recently the main cause of infection has changed from gram-negative to gram-positive bacteria and the resistance to antibiotics has increased. This study aimed to access the effectiveness of antimicrobial prophylaxis (AP) with orally absorbable antibiotics. METHODS: Ninety-five AML patients receiving chemotherapy at Catholic Hemopoietic Stem Cell Transplantation Center from March 1999 to July 1999 were randomly divided into the AP group (250 mg ciprofloxacin twice a day, 150 mg roxithromycin twice a day, 50 mg fluconazole once a day) and the control group for a prospective analysis. RESULTS: The incidence of fever was 82.6% in the AP group and 91.6% in the control group (p=0.15). Though classification and sites of infections showed no difference between the two groups, the catheter associated infection occurred more frequently in the AP group in significance. The time interval between initiation of chemotherapy and onset of fever, white blood cell (WBC) count at the onset of fever, duration of leukopenia (WBC < 1,000/mm ), duration of systemic antibiotic therapy, mortality due to infection and hospitalization period from the data starting chemotherapy showed no differences between the two groups. Infections due to gram negative bacteria decreased to 33.3% in the AP group (vs. 92% in the control group), but infections due to gram positive bacteria increased to 66.7% (vs. 8% in the control group). Gram negative bacteria showed 100% resistance to ciprofloxacin in the AP group and gram-positive bacteria showed 90-100% resistance to erythromycin, regardless of the presence of AP. CONCLUSION: The AP could not reduce the occurrence of infection or infection associated death in AML patients receiving chemotherapy. On considering increased gram-positive infection and resistance to fluoroquinolone and macrolide, routine prescription of AP should be reconsidered. Further studies that assess the effectiveness of AP in other malignancies, aplastic anemia and bone marrow transplantation are required.
Adult
;
Anti-Infective Agents, Fluoroquinolone/*therapeutic use
;
*Antibiotic Prophylaxis
;
Bacterial Infections/epidemiology/etiology/*prevention & control
;
Ciprofloxacin/*therapeutic use
;
Drug Therapy, Combination
;
Female
;
Fever/epidemiology/etiology
;
Fluconazole/therapeutic use
;
Human
;
Incidence
;
Leukemia, Myelocytic, Acute/*complications/drug therapy
;
Male
;
Middle Age
;
Neutropenia/chemically induced/*complications
;
Prospective Studies
;
Roxithromycin/therapeutic use
;
Treatment Outcome